Avandamet sNDA Approved For First-Line Use In Type 2 Diabetics
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s updated label for the rosiglitazone/metformin combination also includes new data concerning risk in congestive heart failure patients.